患者报告与自评神经表现评估多发性硬化不依赖复发的进展
基于多中心MS PATHS队列9088例患者,采用患者确定疾病步骤(PDDS)及自评步行速度、手灵活性和信息处理速度测试定义残疾恶化和不依赖复发活动进展(PIRA)。结果显示45%患者至少一项自评指标恶化,其中58%为PIRA;自评恶化或PIRA与脑萎缩加速、T2病灶体积增加及生活质量更差相关。
要点
- PDDS/自评测试可识别MS残疾恶化和PIRA,45%患者至少一项恶化,58%为PIRA。
- 自评恶化或PIRA与脑萎缩加速、T2病灶体积增加及生活质量更差相关。
核心结论
- PDDS/自评测试定义的恶化和PIRA虽与EDSS定义仅部分一致,但能识别脑损伤更重和生活质量更差的患者,支持临床使用。
研究设计与样本
- 纵向多中心MS PATHS队列研究,纳入9088例患者(73%女性,年龄46.8岁,病程14.2年),需至少3次评估且随访超过6个月。
主要发现
- 3年随访中,4066例(45%)患者至少一项患者报告/自评指标恶化,其中2357例(58%)为PIRA。
- 巴塞罗那亚组279例中,68例(24%)出现EDSS恶化,其中30例(44%)为EDSS-PIRA;99例(35%)至少一项自评测试恶化,其中78例(79%)为PIRA。
- 自评测试恶化或PIRA与脑萎缩加速和T2病灶体积增加相关(p<0.05),且生活质量更差(p<0.05)。
关键数值与推荐
- PIRA定义为PDDS或自评测试(步行速度、手灵活性、信息处理速度)恶化且无自报复发。
- 自评测试恶化或PIRA与脑MRI轨迹和生活质量数据相关系数达到p<0.05。
临床怎么用
- 可将PDDS和自评神经表现测试用于临床实践,辅助识别MS患者残疾恶化和PIRA。
局限性
- 与EDSS定义仅部分一致;巴塞罗那亚组样本量较小(N=279)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to investigate the ability of patient-reported/administered outcomes to capture disability worsening and progression independent of relapse activity (PIRA) in multiple sclerosis (MS). METHODS: We included patients from the longitudinal multicenter MS PATHS cohort with ≥3 assessments and >6 months follow-up. PIRA was defined on the patient-determined disease steps (PDDS) and self-administered tests assessing walking speed, manual dexterity, and processing speed, in the absence of self-reported relapses. We assessed (i) prevalence of PDDS/self-administered test-based disability worsening and PIRA definitions; (ii) their concurrent validity, through the association with worsening and PIRA definitions based on the expanded disability status scale (EDSS; Barcelona subcohort); and (iii) their clinical meaningfulness, through the correlation with brain magnetic resonance imaging (MRI) and quality-of-life (QoL) data trajectories. RESULTS: We included 9,088 patients (73% female patients; age = 46.8 years; disease duration = 14.2 years). Over a 3-year follow-up, 4,066 (45%) patients worsened on ≥1 patient-reported/administered outcome, of which 2,357 (58%) developed PIRA. In the Barcelona subcohort (N = 279), 68 (24%) patients developed EDSS-based worsening, of which 30 (44%) developed EDSS-based PIRA; 99 of 279 (35%) worsened on ≥1 patient-reported/administered test, of which 78 of 99 (79%) had PIRA. Worsening (but not PIRA) on PDDS was associated with EDSS-based worsening (odds ratio = 3.03 [1.42; 6.43], p = 0.004). PDDS/self-administered-test-based worsening or PIRA strongly correlated with accelerated brain atrophy and T2 lesion volume increase compared to non-worseners (p < 0.05), and showed worse QoL (p < 0.05). INTERPRETATION: Despite only partial agreement with EDSS-based definitions, PDDS/self-administered test-based worsening and PIRA definitions were clinically meaningful, by identifying patients with greater brain damage and poorer QoL, supporting their use in clinical practice. ANN NEUROL 2026;100:525-546.
引用
- Reinders EM, Masot-Llima A, Otero-Romero S, et al. Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes. Ann Neurol. 2026. PMID: 42405485. doi:10.1002/ana.78275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。